CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CARsgen Therapeutics Holdings Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Total Current Liabilities
ÂĄ196.2m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Liabilities
ÂĄ4.1B
CAGR 3-Years
23%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
71%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Total Current Liabilities?
Total Current Liabilities
196.2m CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Total Current Liabilities amounts to 196.2m CNY.

What is CARsgen Therapeutics Holdings Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
11%

Over the last year, the Total Current Liabilities growth was 15%. The average annual Total Current Liabilities growth rates for CARsgen Therapeutics Holdings Ltd have been 11% over the past three years .

Back to Top